Arkolith/Insider Trading/STRO/Form 4

Gerber Hans-Peter

CHIEF SCIENTIFIC OFFICERSUTRO BIOPHARMA, INC. (STRO) · full profile →Form 4 · filed Mar 3, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
8
4 non-derivative · 4 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 2, 2026Option exercise(M)3K—$011K
Mar 2, 2026Tax withholding(F)1K$20.55$24K10K
Mar 1, 2026Tax withholding(F)463$20.47$9K8K
Mar 1, 2026Option exercise(M)1K—$08K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 2, 2026Grant(A)5K—$05K
Mar 2, 2026Grant(A)40K—$040K
Mar 2, 2026Option exercise(M)3K—$09K
Mar 1, 2026Option exercise(M)1K—$02K

Transaction Codes

M
Option exercise / conversion
F
Shares withheld for taxes
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001992979-26-000002) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML